DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

0.79 0.03 (3.67%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PLX $0.79 3.67%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.80
Previous Close $0.76
Daily Range $0.75 - $0.82
52-Week Range $0.74 - $2.35
Market Cap $78.6M
P/E Ratio -2.81
Dividend (Yield) $0.00 (0.0%)
Volume 62,622
Average Daily Volume 128,081
Current FY EPS $0.45

Sector

Healthcare

Industry

Drug Makers

Protalix BioTherapeutics, Inc. (PLX) Description

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system. Website: http://www.protalix.com/

News & Commentary Rss Feed

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

Protalix Meets FDA, To Start Phase III Fabry Disease Study

Protalix BioTherapeutics (PLX) Jumps: Stock Rises 8.7%

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

Morning Market Gainers

Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its P

Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

Protalix's Phase I/II Fabry Disease Study Interim Data Positive

US Stock Futures Point To Higher Open

Protalix BioTherapeutics Announces Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of

Protalix BioTherapeutics Announces Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Pr

Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity

See More PLX News...

PLX's Top Competitors

PLX $0.79 (3.67%)
Current stock: PLX
AMGN $144.72 (2.30%)
Current stock: AMGN
GILD $89.44 (2.38%)
Current stock: GILD
BIIB $247.22 (0.86%)
Current stock: BIIB